Sunday, November 29, 2020

Volunteer in Covid vaccine test dies in Brazil

It is the first death reported in the various coronavirus vaccine trials taking place worldwide.

Other News

1,315 kes baru Covid-19, 1,110 pulih, 4 lagi kematian dilaporkan

Sebanyak 11,508 kes aktif direkodkan.

1,315 new cases, 476 in Sabah

Four more deaths take virus toll to 354.

Peruntukan “durian runtuh” Jasa dicantas separuh selepas nama, imej ditukar

Pengumuman pengurangan itu dijangka diumumkan ketika ucapan penggulungan peringkat jawatankuasa minggu depan.

With new name and image, Jasa’s ‘windfall’ budget to be halved

The RM85.5 million allocation, which came under criticism following its announcement on Nov 6, could be cut down by RM40 million, sources say.

Pengusaha tadika terjejas ‘terkapai-kapai’ tanpa bantuan

Pengusaha luah kekesalan kerana tidak diberikan bantuan kerajaan walaupun terjejas teruk sejak pelaksanaan Perintah Kawalan Pergerakan.

A volunteer participating in clinical trials of the Covid-19 vaccine developed by Oxford University has died in Brazil, officials announced Wednesday, though media reports said he had received a placebo, not the test vaccine.

It is the first death reported in the various coronavirus vaccine trials taking place worldwide.

However, organisers of the study said an independent review had concluded there were no safety concerns and that testing of the vaccine, developed with pharmaceutical firm AstraZeneca, would continue.

Media reports said the volunteer was a 28-year-old doctor working on the front lines of the pandemic who died of complications from Covid-19.

Brazilian newspaper Globo and international news agency Bloomberg said he was in the control group and had received a placebo rather than the test vaccine, citing sources close to the trials.

“Following careful assessment of this case in Brazil, there have been no concerns about safety of the clinical trial, and the independent review in addition to the Brazilian regulator have recommended that the trial should continue,” Oxford said in a statement.

AstraZeneca said medical confidentiality meant it could not give details on any individual volunteer, but that independent review had “not led to any concerns about continuation of the ongoing study”.

Brazil’s national health regulator, Anvisa, confirmed it had been notified of the case on Oct 19.

The D’Or Teaching and Research Institute (Idor), which is helping organise the tests in Brazil, said the independent review had “raised no doubts about the safety of the study, and recommended it continue”.

Oxford and AstraZeneca previously had to suspend testing of the vaccine in September when a volunteer in Britain developed an unexplained illness.

Trials resumed after British regulators and an independent review concluded the illness was not a side effect of the vaccine.

Half the volunteers in the final-stage clinical trial – a double-blind, randomised, controlled study – receive a placebo, Idor said.

Around 8,000 volunteers have been vaccinated so far in Brazil, and more than 20,000 worldwide, it said.

Study participants must be doctors, nurses or other health sector workers who come into regular contact with the virus.

The deceased volunteer was a young doctor who had been treating Covid-19 patients since March in the emergency rooms and intensive care units at two hospitals in Rio de Janeiro, Globo said.

He graduated from medical school last year, and was in good health prior to contracting the disease, family and friends told the newspaper.

Subscribe to our newsletter

To be updated with all the latest news and analyses.

Related Articles

1,315 new cases, 476 in Sabah

Four more deaths take virus toll to 354.

New cases back to 4 digits at 1,109

However, recoveries outnumber new cases at 1,148.

Court throws out Umno man’s bid to strike out suit by Teresa Kok

A three-member Court of Appeal panel dismissed Jamal Yunos' appeal and ordered him to pay Teresa Kok RM7,000 in costs.

Germany’s Covid-19 infections pass 1 million

The number of Covid-19 patients in intensive care nationwide has soared from just over 360 in early October to more than 3,500 last week.

935 new cases, recoveries surge to 2,555

Sabah accounts for 35% of new cases and Selangor 17%.